U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. GAMMAGARD LIQUID
  1. Approved Blood Products

GAMMAGARD LIQUID

STN: BL 125105
Proper Name: Immune Globulin Infusion (Human)
Tradename: GAMMAGARD LIQUID
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Indication:

GAMMAGARD LIQUID is an immune globulin infusion (human) indicated as a:

  • Replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.
  • Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).
  • Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Product Information

Supporting Documents

Back to Top